The intestinal lining is exposed to constant mechanical and chemical stress. Cells are regularly shed and must be replaced by intestinal stem cells, which generate both new stem cells and the specialized epithelial cells responsible for absorbing nutrients, producing mucus, and maintaining the gut barrier. When injury destroys too many stem cells, mature intestinal cells can reverse their specialized identities through a process known as cellular plasticity. They temporarily enter a stress-associated state before reverting to a regenerative, stem-cell-like condition.

The new study, published in Nature, identifies ZFP36L2 as a key molecular regulator of this transition. The protein belongs to a family of RNA-binding proteins that control the stability and fate of messenger RNA molecules. As intestinal cells mature, ZFP36L2 activity declines, helping stabilize their specialized identities. When tissue damage occurs, the protein becomes essential for ending the emergency response that initially prevents cells from changing identity.

At the molecular level, ZFP36L2 binds messenger RNAs carrying stress-response signals and directs them toward cellular compartments where they can be degraded. This process reduces the amount of stress-related RNA available for translation into proteins, effectively turning down the alarm. According to the researchers, this timing is critical: the stress response must be activated rapidly after injury, but it must also be shut off before a cell can complete its transition into a regenerative state.

Experiments in genetically engineered mice demonstrated the importance of this mechanism. Animals lacking ZFP36L2 were unable to recover efficiently from experimentally induced intestinal injury. Their cells remained trapped in a prolonged stress state and failed to replenish the stem-cell population needed to restore the damaged tissue. The findings suggest that ZFP36L2 functions less like a simple on-off switch and more like a molecular timing system, coordinating the shift from damage detection to tissue repair.

The same cellular flexibility appears to be important when colorectal cancer spreads. To form a metastasis, tumor cells must survive separation from the primary tumor, travel through the bloodstream, adapt to a foreign tissue environment, and begin producing new cancer cells. This journey exposes them to conditions resembling injury, including oxidative stress, nutrient deprivation, and immune attack. The MSK team found that metastatic colorectal cancer cells rely on ZFP36L2 to suppress this stress state and regain a stem-cell-like identity after reaching organs such as the liver or lungs.

Researchers tested the process using organoids derived from patient colorectal cancer liver metastases. These three-dimensional laboratory models preserve many of the biological features of the original tumors. When ZFP36L2 was depleted, the cancer cells showed a sharply reduced ability to establish metastases in mice. This effect was not simply the result of smaller primary tumors: tumors lacking the protein often failed to seed distant organs even when the original tumors were comparable in size or larger than control tumors. The result points to a specific defect in metastatic colonization rather than a general failure of tumor growth.

ZFP36L2 appears to have a more complicated role in primary colorectal tumors. Removing the protein slowed tumor growth, indicating that some cancer cells depend on it to maintain their usual stem-cell identity and produce additional tumor cells. Yet tumors with naturally occurring ZFP36L2 mutations or deletions—alterations reported in approximately 5% to 10% of colorectal cancer patients—can become more adaptable in another way. Instead of remaining in a conventional colorectal cancer state, they may shift toward abnormal neuroendocrine-like or squamous-like identities.

These alternate cell states are associated with treatment resistance and poorer clinical outcomes. The researchers propose that when cancer cells cannot use ZFP36L2 to complete the transition back to a stem-cell program, they remain under persistent stress. That pressure may favor rare cells capable of changing identity and surviving therapy. The finding illustrates why targeting a cancer dependency can be biologically complex: eliminating ZFP36L2 might interfere with metastasis, but gradual loss of the protein in an established tumor could also encourage the emergence of more aggressive, therapy-resistant cell types.

The researchers are now exploring whether ZFP36L2 can be targeted therapeutically in a controlled way. A rapid, precisely timed disruption could potentially overwhelm metastatic cells before they adapt, causing them to collapse under their own stress burden. At the same time, the protein’s role in healthy tissue repair means that any treatment would need to avoid damaging the intestine’s normal regenerative capacity. Because ZFP36L2 mutations can be detected through tumor sequencing, the discovery may also help identify patients whose cancers are more likely to develop unusual, treatment-resistant characteristics. More broadly, related proteins are altered in a significant fraction of solid tumors, raising the possibility that the stress-adaptation mechanism could extend beyond colorectal cancer.

Subject of Research: ZFP36L2 regulation of intestinal regeneration, cellular plasticity, colorectal cancer progression, and metastasis

Article Title: ZFP36L2 orchestrates stress-adaptive plasticity in regeneration and cancer

News Publication Date: 5 August 2026

Web References:
https://www.nature.com/articles/s41586-026-10890-0
https://www.mskcc.org/research-areas/labs/karuna-ganesh
https://www.mskcc.org/research-areas/labs/members/qingwen-jiang

References:
Jiang, Q. et al. “ZFP36L2 orchestrates stress-adaptive plasticity in regeneration and cancer.” Nature. DOI: 10.1038/s41586-026-10890-0.

Image Credits: Ganesh Lab, Memorial Sloan Kettering Cancer Center

Keywords: ZFP36L2, colorectal cancer, cancer metastasis, intestinal stem cells, cellular plasticity, tissue regeneration, stress response, cancer organoids, treatment resistance, Memorial Sloan Kettering Cancer Center

The journey of eIF4G2 began decades ago when Yamanaka recognized its essential role in embryonic development. Early mouse models revealed embryonic lethality in the absence of eIF4G2, hinting at its fundamental importance. Yet, the inability to study its function in adult organisms left many questions unanswered. Today’s CRISPR-based model circumvents this by selectively deactivating the gene post-development, enabling unprecedented insights into its mechanisms within mature tissues.

Adult stem cells residing in the intestinal lining are pivotal for continuous regeneration, sustaining digestive functions, and mounting defenses against pathogens. These cells rely on an intricate balance of protein synthesis to maintain their identity and differentiate into specialized intestinal cell types. Yamanaka’s research reveals that eIF4G2 acts as a critical regulator at the translational level, selectively ensuring the production of a subset of proteins, particularly chromatin regulators that govern gene expression programs, thus safeguarding stem cell identity.

Through meticulous experimentation, the study unveils that the deletion of eIF4G2 in adult mice causes a profound translational downregulation. This diminishes the output of essential proteins below functional thresholds, triggering adult intestinal stem cells to lose their specialized adult characteristics. Instead, they revert to a fetal-like, undifferentiated state—an embryonic reminiscence that hinders their ability to mature and fulfill vital physiological roles.

Intriguingly, while this reversion echoes biological repair processes following intestinal injury—such as those induced by radiation or chemotherapy—it differs profoundly in persistence. Normally, the fetal-like state is transient, facilitating effective tissue repair before stem cells revert to their adult form. However, eIF4G2-deficient cells remain locked in this primitive state, unable to progress towards functional differentiation, an insight that deepens our understanding of stem cell plasticity and its limits.

Notably, the physical architecture of the intestine remains surprisingly preserved for extended periods despite the stem cells’ failure to mature. This dissociation between tissue structure and function underscores the gene’s critical role in cell identity regulation rather than mere tissue integrity. The predominant presence of immature cells within the stem cell niche opens a new window for probing the cellular and molecular transitions that underpin tissue homeostasis and regeneration.

This study challenges long-standing notions of genes like eIF4G2 as mere “housekeepers” essential for basic cellular survival. Instead, it positions them as precise modulators orchestrating the selective translation of protein subsets fundamental to determining cell fate. This refined perspective not only broadens our comprehension of translational control but also introduces new molecular targets for manipulating stem cell behavior.

Given eIF4G2’s expression in diverse tissues, the implications extend beyond the intestine. Yamanaka’s team aims to leverage their novel animal model to disentangle the gene’s functions in other vital organs, including bone marrow and heart—tissues with profound regenerative potential and clinical importance. Such investigations promise to unlock new therapeutic avenues for myriad degenerative diseases and injuries.

The broader significance of this research lies in its contribution to regenerative medicine. By illuminating the molecular switches that govern the oscillation between adult and fetal-like states during tissue repair, the findings offer transformative insights. This precise understanding holds the promise of devising therapies that can manipulate cellular reprogramming with exquisite control, potentially revolutionizing treatments for organ failure and chronic conditions.

Moreover, this pioneering work provides a powerful experimental framework to demystify the dynamic and often chaotic processes of tissue regeneration. By enabling focused interrogation of cell fate transitions, it paves the way for designing interventions that could enhance repair while avoiding pathological reprogramming that might contribute to diseases like cancer.

In sum, Yamanaka’s comeback investigation into eIF4G2 exemplifies how technological advances can revive and redefine earlier scientific questions, transforming them into rich fields of inquiry with clinical resonance. The blending of sophisticated genetic engineering with deep biological insights heralds a new chapter in stem cell research—one where understanding the minutiae of translational control could unlock the secrets of regeneration and cellular identity.

As this elegant study moves from fundamental discovery towards potential clinical applications, it reaffirms Gladstone Institutes’ standing at the forefront of combining visionary science with impactful medicine. Shinya Yamanaka’s work continues to inspire a molecular renaissance in regenerative biology, spotlighting the indispensable role of seemingly humble genes in the grand theater of life and healing.

Subject of Research: eIF4G2 gene function in adult intestinal stem cells and cellular identity maintenance

Article Title: eIF4G2-Mediated Selective Translation of Chromatin Regulators Safeguards Adult Intestinal Stem Cell Identity and Differentiation

News Publication Date: April 30, 2026

Web References:
https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(26)00146-3
http://dx.doi.org/10.1016/j.stem.2026.04.006

Image Credits: Gladstone Institutes

Keywords

Regenerative medicine, Stem cells, Gastrointestinal tract, Digestive disorders, Intestines, Nobel prizes, Drug discovery, Drug targets